查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生物製品市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按产品、应用、来源、製造和地理位置
市场调查报告书
商品编码
1558417

生物製品市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按产品、应用、来源、製造和地理位置

Biologics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Application, Source, Manufacturing, and Geography
出版日期: | 出版商: The Insight Partners | 英文 200 Pages | 订单完成后即时交付

价格

根据我们关于「2031 年生物製剂市场预测 - 全球分析 - 按产品、应用、来源、製造和地理位置」的新研究，该市场预计将从 2023 年的 4692 亿美元增长到 2023 年的 4692 亿美元。到2031 年将达到17,939 亿；预计 2023-2031 年复合年增长率为 18.2%。市场成长归因于慢性病病例的增加以及随后多种疾病缓解疗法的批准。发展中地区生物技术产业的发展可能为市场成长提供机会。然而，严格的法规和高昂的药物开发成本阻碍了市场的成长。

生物製剂是製药业最有前景的途径之一，提供了治疗各种疾病和医疗状况的独特方法。由于製药和生技公司投入大量资金改善其生产设施，生物製品市场不断成长。慢性病病例和诊断数量的增加需要复杂的诊断和治疗药物的供应，这推动了全球生物製品市场的发展。此外，不断增长的需求、对创新疗法的更高接受度以及不断增加的临床试验预计将推动市场成长。然而，生物相似药的批准是限制生物製剂市场扩张的主要方面之一。

2023年，北美占据全球生物製品市场的主要份额。推动该地区市场成长的关键因素是慢性病的高盛行率、众多领先的生物製药公司、有利的报销政策以及对研发的大量投资。根据 JAMA Network 发表的一篇文章，生物製剂占美国药品总支出的 37%。生物製剂处方份额的不断增加以及对开发标靶药物的投资不断增加正在促进市场成长。此外，反义、基因疗法和 RNAi 疗法等几种新型生物药物的批准预计将进一步推动市场成长。

发展中地区生技产业的发展为未来提供市场机会

在现代生物技术中，从基础研究到创新医学评估的许多过程都需要抗体。治疗性抗体的开发为治疗各种疾病开闢了新途径，证明了这些颗粒的转化能力。抗体在基于抗体的诊断中也至关重要，因为它们提供了准确可靠的疾病识别方法。政府不断增加的支持、不断增加的公私伙伴关係、不断变化的疾病概况以及不断增加的资助活动正在广泛提高亚太地区、南美洲和中美洲以及中东和非洲等地区生物技术行业的绩效。阿联酋、沙乌地阿拉伯、阿曼、马斯喀特、巴林、台湾、马来西亚、印度、中国、新加坡和日本等国家是生物技术产业最有利的目的地之一。生物技术、遗传学和细胞生物学领域的不断进步有助于确定标靶治疗的潜力。随着生物技术产业扩大科学家的工具箱，基础研究、转化研究和临床试验的结合将继续开发、研究和测试更多的化合物、技术和治疗途径。生物技术是中国的战略产业。中国製造2025计划旨在生产高科技产品，包括创新药物。该计划为中国製药公司提出了刺激生物技术创新和增加出口的目标。此外，这些亚洲国家更注重利用基因组学、蛋白质组学和生物标记的进步进行诊断和治疗应用。因此，发展中地区生物技术产业的持续发展预计将在未来几年为生物製品市场创造机会。

基于产品的见解

根据产品，生物製品市场分为单株抗体、疫苗、重组荷尔蒙/蛋白质、细胞和基因治疗等。单株抗体细分市场在 2023 年占据最大的市场份额，并且可能在 2023 年至 2031 年期间实现最高的复合年增长率。

基于应用程式的见解

根据应用，市场分为癌症、传染病、自体免疫疾病等。 2023 年，癌症细分市场占据最大市场份额，预计 2023 年至 2031 年复合年增长率最高。

基于来源的见解

根据来源，市场分为哺乳动物和微生物。微生物细分市场将在 2023 年占据更大的市场份额。哺乳动物表达系统主要用于开发基于病毒载体的重组蛋白和疫苗。最常用的哺乳动物细胞係是 CHO 和 HEK。 Perjeta（帕妥珠单抗）、Adcetris（brentuximab vedotin）、Kadycla（曲妥珠单抗emtansine）、Shingrix（带状疱疹疫苗）和Aimovig（erenumab）等产品都是在哺乳动物表达系统中生产的产品。

生物製剂市场：竞争格局与主要发展

艾伯维公司；辉瑞公司；三星生物製剂； ADMA 生物製剂公司；药明生物；康泰伦特公司； AGC生物製剂； Crescendo 生物製剂有限公司； Zumutor 生物製品公司； Theriva 生物製剂；阿斯特捷利康；安进公司；艾维西亚生物製品公司；和 Quality Assistance sa 是生物製剂市场上的主要公司之一。

美国食品药物管理局、疾病管制与预防中心 (CDC) 和全球疾病负担研究是准备生物製剂市场报告时参考的主要和次要来源。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解

第 3 章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第 4 章：生物製品市场格局

  • 概述
  • PEST分析

第 5 章：生物製剂市场 - 主要市场动态

  • 生物製品市场 - 主要市场动态
  • 市场驱动因素
    • 慢性病盛行率增加
    • 偏好外包製造业务
  • 市场限制
    • 生物製剂成本高
  • 市场机会
    • 发展中地区生物技术的演变
  • 未来趋势
    • 公司的策略倡议
  • 驱动因素和限制的影响：

第 6 章：生物製剂市场 - 全球市场分析

  • 生物製品市场收入，2021-2031
  • 生物製品市场预测分析

第 7 章：生物製剂市场分析 - 按产品

  • 单株抗体
  • 疫苗
  • 重组荷尔蒙/蛋白质
  • 细胞和基因治疗
  • 其他的

第 8 章：生物製剂市场分析 - 按应用

  • 癌症
  • 传染病
  • 自体免疫疾病
  • 其他的

第 9 章：生物製品市场分析 - 按来源

  • 哺乳动物
  • 微生物

第 10 章：生物製剂市场分析 - 按製造

  • 外包
  • 内部

第 11 章：生物製品市场 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 亚太地区其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 12 章：产业格局

  • 概述
  • 生物製品市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 13 章：公司简介

  • AbbVie Inc
  • Pfizer Inc
  • Samsung Biologics Co Ltd
  • ADMA Biologics, Inc.
  • WuXi Biologics Inc
  • Catalent Inc
  • AGC Biologics AS
  • AstraZeneca Plc
  • Amgen Inc
  • Nitto Avecia
  • Quality Assistance s.a.

第 14 章：附录

Product Code: TIPRE00002765

According to our new research study on "Biologics Market Forecast to 2031 - Global Analysis - by Product, Application, Source, Manufacturing, and Geography," the market is anticipated to grow from US$ 469.2 billion in 2023 and is projected to reach US$ 1,793.9 billion by 2031; it is expected to register a CAGR of 18.2% during 2023-2031. Market growth is attributed to increasing cases of chronic diseases and subsequent approvals for several disease-modifying therapies. Evolution of biotechnology industry in developing regions are likely to offer opportunities for the market growth. However, the stringent regulations and high drug development costs hinder the growth of the market.

Biologics are among the most promising avenues in the pharmaceutical industry, offering a unique approach to treating various diseases and medical conditions. The biologics market is constantly growing because pharma and biotechnology companies enormously invest in improving their production facilities. The increasing number of cases and diagnoses of chronic diseases requires the availability of sophisticated diagnostic and treatment drugs, which has boosted the global biologics market. Furthermore, rising demand, higher acceptance of innovative therapies, and increasing clinical trials are expected to drive market growth. However, approving biosimilars is one of the main aspects limiting the biologics market expansion.

North America accounted for a major share of the global biologics market in 2023. The North America biologics market is segmented into the US, Canada, and Mexico. The key factors driving the market growth in this region is the high prevalence of chronic diseases, numerous leading biopharmaceutical companies, favorable reimbursement policies, and significant investments in research and development. According to an article published in JAMA Network, biologics accounted for 37% of total drug spending in the US. The increasing share of prescriptions for biologics and growing investments in developing targeted drugs are contributing to the market growth. Additionally, approvals for several novel biological drugs such as antisense, gene therapy, and RNAi therapeutics are expected to drive market growth further.

Evolution of Biotechnology Industry in Developing Regions to Provide Market Opportunities in Future

In modern biotechnology, antibodies are required in numerous processes, from basic research to innovative medical evaluations. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in antibody-based diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of the biotechnology industry in regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most advantageous destinations for the biotechnology industry. Continuous advancements in the fields of biotechnology, genetics, and cell biology have contributed to identifying the potential of therapeutics for targeted therapies. As the biotechnology industry expands scientists' toolboxes, the combination of basic research, translational studies, and clinical trials will continue to develop, investigate, and test additional compounds, techniques, and therapeutic pathways. Biotechnology is a strategic sector for China. The Made in China 2025 initiative aims to produce high-tech products, including innovative medicines. The plan introduced targets for Chinese pharmaceutical companies to spur biotechnology innovation and increase exports. Furthermore, these Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing evolution of the biotechnology industry in developing regions is expected to create opportunities for the biologics market in the coming years.

Product -Based Insights

Based on product, the biologics market is divided into monoclonal antibodies, vaccines, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023 and is likely to register the highest CAGR during 2023-2031.

Application -Based Insights

The market, based on application, is divided into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest share of the market in 2023 and is anticipated to register the highest CAGR during 2023-2031.

Source -Based Insights

Based on source, the market is segmented into mammalian and microbial. The microbial segment held a larger market share in 2023. The mammalian is estimated to record a faster CAGR during 2023-2031. Mammalian expression systems are mainly used to develop recombinant proteins and vaccines based on viral vectors. The most frequently used mammalian cell lines are CHO and HEK. Products such as Perjeta (pertuzumab), Adcetris (brentuximab vedotin), Kadycla (trastuzumab emtansine), Shingrix (zoster vaccine), and Aimovig (erenumab) are among the products manufactured in mammalian expression systems.

Biologics Market: Competitive Landscape and Key Developments

AbbVie Inc.; Pfizer Inc.; Samsung Biologics; ADMA Biologics, Inc.; WuXi Biologics; Catalent, Inc; AGC Biologics; Crescendo Biologics Limited; Zumutor Biologics INC; Theriva Biologics; AstraZeneca; Amgen Inc.; Avecia Biologics; and Quality Assistance s.a. are among the key companies operating in the biologics market.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the biologics market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Biologics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Biologics Market - Key Market Dynamics

  • 5.1 Biologics Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Increasing Prevalence of Chronic Diseases
    • 5.2.2 Preference for Outsourcing Manufacturing Operations
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Biologics
  • 5.4 Market Opportunities
    • 5.4.1 Evolution of Biotechnology in Developing Regions
  • 5.5 Future Trends
    • 5.5.1 Strategic Initiatives by Companies
  • 5.6 Impact of Drivers and Restraints:

6. Biologics Market - Global Market Analysis

  • 6.1 Biologics Market Revenue (US$ Million), 2021-2031
  • 6.2 Biologics Market Forecast Analysis

7. Biologics Market Analysis - by Product

  • 7.1 Monoclonal Antibodies
    • 7.1.1 Overview
    • 7.1.2 Monoclonal Antibodies: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Vaccine
    • 7.2.1 Overview
    • 7.2.2 Vaccine: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Recombinant Hormones/Proteins
    • 7.3.1 Overview
    • 7.3.2 Recombinant Hormones/Proteins: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Cell and Gene Therapy
    • 7.4.1 Overview
    • 7.4.2 Cell and Gene Therapy: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

8. Biologics Market Analysis - by Application

  • 8.1 Cancer
    • 8.1.1 Overview
    • 8.1.2 Cancer: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Infectious Diseases
    • 8.2.1 Overview
    • 8.2.2 Infectious Diseases: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Autoimmune Diseases
    • 8.3.1 Overview
    • 8.3.2 Autoimmune Diseases: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

9. Biologics Market Analysis - by Source

  • 9.1 Mammalian
    • 9.1.1 Overview
    • 9.1.2 Mammalian: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Microbial
    • 9.2.1 Overview
    • 9.2.2 Microbial: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

10. Biologics Market Analysis - by Manufacturing

  • 10.1 Outsourced
    • 10.1.1 Overview
    • 10.1.2 Outsourced: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 In-house
    • 10.2.1 Overview
    • 10.2.2 In-house: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

11. Biologics Market - Geographical Analysis

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 North America Biologics Market Overview
    • 11.2.2 North America: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.2.3 North America: Biologics Market Breakdown, by Product
      • 11.2.3.1 North America: Biologics Market - Revenue and Forecast Analysis - by Product
    • 11.2.4 North America: Biologics Market Breakdown, by Application
      • 11.2.4.1 North America: Biologics Market - Revenue and Forecast Analysis - by Application
    • 11.2.5 North America: Biologics Market Breakdown, by Source
      • 11.2.5.1 North America: Biologics Market - Revenue and Forecast Analysis - by Source
    • 11.2.6 North America: Biologics Market Breakdown, by Manufacturing
      • 11.2.6.1 North America: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
    • 11.2.7 North America: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.1 North America: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.2 United States: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.2.1 United States: Biologics Market Breakdown, by Product
        • 11.2.7.2.2 United States: Biologics Market Breakdown, by Application
        • 11.2.7.2.3 United States: Biologics Market Breakdown, by Source
        • 11.2.7.2.4 United States: Biologics Market Breakdown, by Manufacturing
      • 11.2.7.3 Canada: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.3.1 Canada: Biologics Market Breakdown, by Product
        • 11.2.7.3.2 Canada: Biologics Market Breakdown, by Application
        • 11.2.7.3.3 Canada: Biologics Market Breakdown, by Source
        • 11.2.7.3.4 Canada: Biologics Market Breakdown, by Manufacturing
      • 11.2.7.4 Mexico: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.4.1 Mexico: Biologics Market Breakdown, by Product
        • 11.2.7.4.2 Mexico: Biologics Market Breakdown, by Application
        • 11.2.7.4.3 Mexico: Biologics Market Breakdown, by Source
        • 11.2.7.4.4 Mexico: Biologics Market Breakdown, by Manufacturing
  • 11.3 Europe
    • 11.3.1 Europe Biologics Market Overview
    • 11.3.2 Europe: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.3.3 Europe: Biologics Market Breakdown, by Product
      • 11.3.3.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Product
    • 11.3.4 Europe: Biologics Market Breakdown, by Application
      • 11.3.4.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Application
    • 11.3.5 Europe: Biologics Market Breakdown, by Source
      • 11.3.5.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Source
    • 11.3.6 Europe: Biologics Market Breakdown, by Manufacturing
      • 11.3.6.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
    • 11.3.7 Europe: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.2 Germany: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.2.1 Germany: Biologics Market Breakdown, by Product
        • 11.3.7.2.2 Germany: Biologics Market Breakdown, by Application
        • 11.3.7.2.3 Germany: Biologics Market Breakdown, by Source
        • 11.3.7.2.4 Germany: Biologics Market Breakdown, by Manufacturing
      • 11.3.7.3 United Kingdom: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.3.1 United Kingdom: Biologics Market Breakdown, by Product
        • 11.3.7.3.2 United Kingdom: Biologics Market Breakdown, by Application
        • 11.3.7.3.3 United Kingdom: Biologics Market Breakdown, by Source
        • 11.3.7.3.4 United Kingdom: Biologics Market Breakdown, by Manufacturing
      • 11.3.7.4 Italy: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.4.1 Italy: Biologics Market Breakdown, by Product
        • 11.3.7.4.2 Italy: Biologics Market Breakdown, by Application
        • 11.3.7.4.3 Italy: Biologics Market Breakdown, by Source
        • 11.3.7.4.4 Italy: Biologics Market Breakdown, by Manufacturing
      • 11.3.7.5 France: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.5.1 France: Biologics Market Breakdown, by Product
        • 11.3.7.5.2 France: Biologics Market Breakdown, by Application
        • 11.3.7.5.3 France: Biologics Market Breakdown, by Source
        • 11.3.7.5.4 France: Biologics Market Breakdown, by Manufacturing
      • 11.3.7.6 Spain: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.6.1 Spain: Biologics Market Breakdown, by Product
        • 11.3.7.6.2 Spain: Biologics Market Breakdown, by Application
        • 11.3.7.6.3 Spain: Biologics Market Breakdown, by Source
        • 11.3.7.6.4 Spain: Biologics Market Breakdown, by Manufacturing
      • 11.3.7.7 Rest of Europe: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.7.1 Rest of Europe: Biologics Market Breakdown, by Product
        • 11.3.7.7.2 Rest of Europe: Biologics Market Breakdown, by Application
        • 11.3.7.7.3 Rest of Europe: Biologics Market Breakdown, by Source
        • 11.3.7.7.4 Rest of Europe: Biologics Market Breakdown, by Manufacturing
  • 11.4 Asia Pacific
    • 11.4.1 Asia Pacific Biologics Market Overview
    • 11.4.2 Asia Pacific: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.4.3 Asia Pacific: Biologics Market Breakdown, by Product
      • 11.4.3.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Product
    • 11.4.4 Asia Pacific: Biologics Market Breakdown, by Application
      • 11.4.4.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Application
    • 11.4.5 Asia Pacific: Biologics Market Breakdown, by Source
      • 11.4.5.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Source
    • 11.4.6 Asia Pacific: Biologics Market Breakdown, by Manufacturing
      • 11.4.6.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
    • 11.4.7 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.4.7.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.4.7.2 China: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.2.1 China: Biologics Market Breakdown, by Product
        • 11.4.7.2.2 China: Biologics Market Breakdown, by Application
        • 11.4.7.2.3 China: Biologics Market Breakdown, by Source
        • 11.4.7.2.4 China: Biologics Market Breakdown, by Manufacturing
      • 11.4.7.3 India: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.3.1 India: Biologics Market Breakdown, by Product
        • 11.4.7.3.2 India: Biologics Market Breakdown, by Application
        • 11.4.7.3.3 India: Biologics Market Breakdown, by Source
        • 11.4.7.3.4 India: Biologics Market Breakdown, by Manufacturing
      • 11.4.7.4 Japan: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.4.1 Japan: Biologics Market Breakdown, by Product
        • 11.4.7.4.2 Japan: Biologics Market Breakdown, by Application
        • 11.4.7.4.3 Japan: Biologics Market Breakdown, by Source
        • 11.4.7.4.4 Japan: Biologics Market Breakdown, by Manufacturing
      • 11.4.7.5 South Korea: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.5.1 South Korea: Biologics Market Breakdown, by Product
        • 11.4.7.5.2 South Korea: Biologics Market Breakdown, by Application
        • 11.4.7.5.3 South Korea: Biologics Market Breakdown, by Source
        • 11.4.7.5.4 South Korea: Biologics Market Breakdown, by Manufacturing
      • 11.4.7.6 Australia: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.6.1 Australia: Biologics Market Breakdown, by Product
        • 11.4.7.6.2 Australia: Biologics Market Breakdown, by Application
        • 11.4.7.6.3 Australia: Biologics Market Breakdown, by Source
        • 11.4.7.6.4 Australia: Biologics Market Breakdown, by Manufacturing
      • 11.4.7.7 Rest of APAC: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.7.1 Rest of APAC: Biologics Market Breakdown, by Product
        • 11.4.7.7.2 Rest of APAC: Biologics Market Breakdown, by Application
        • 11.4.7.7.3 Rest of APAC: Biologics Market Breakdown, by Source
        • 11.4.7.7.4 Rest of APAC: Biologics Market Breakdown, by Manufacturing
  • 11.5 Middle East and Africa
    • 11.5.1 Middle East and Africa Biologics Market Overview
    • 11.5.2 Middle East and Africa: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.5.3 Middle East and Africa: Biologics Market Breakdown, by Product
      • 11.5.3.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Product
    • 11.5.4 Middle East and Africa: Biologics Market Breakdown, by Application
      • 11.5.4.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Application
    • 11.5.5 Middle East and Africa: Biologics Market Breakdown, by Source
      • 11.5.5.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Source
    • 11.5.6 Middle East and Africa: Biologics Market Breakdown, by Manufacturing
      • 11.5.6.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
    • 11.5.7 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.5.7.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.5.7.2 South Africa: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.2.1 South Africa: Biologics Market Breakdown, by Product
        • 11.5.7.2.2 South Africa: Biologics Market Breakdown, by Application
        • 11.5.7.2.3 South Africa: Biologics Market Breakdown, by Source
        • 11.5.7.2.4 South Africa: Biologics Market Breakdown, by Manufacturing
      • 11.5.7.3 Saudi Arabia: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.3.1 Saudi Arabia: Biologics Market Breakdown, by Product
        • 11.5.7.3.2 Saudi Arabia: Biologics Market Breakdown, by Application
        • 11.5.7.3.3 Saudi Arabia: Biologics Market Breakdown, by Source
        • 11.5.7.3.4 Saudi Arabia: Biologics Market Breakdown, by Manufacturing
      • 11.5.7.4 United Arab Emirates: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.4.1 United Arab Emirates: Biologics Market Breakdown, by Product
        • 11.5.7.4.2 United Arab Emirates: Biologics Market Breakdown, by Application
        • 11.5.7.4.3 United Arab Emirates: Biologics Market Breakdown, by Source
        • 11.5.7.4.4 United Arab Emirates: Biologics Market Breakdown, by Manufacturing
      • 11.5.7.5 Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.5.1 Rest of Middle East and Africa: Biologics Market Breakdown, by Product
        • 11.5.7.5.2 Rest of Middle East and Africa: Biologics Market Breakdown, by Application
        • 11.5.7.5.3 Rest of Middle East and Africa: Biologics Market Breakdown, by Source
        • 11.5.7.5.4 Rest of Middle East and Africa: Biologics Market Breakdown, by Manufacturing
  • 11.6 South and Central America
    • 11.6.1 South and Central America Biologics Market Overview
    • 11.6.2 South and Central America: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.6.3 South and Central America: Biologics Market Breakdown, by Product
      • 11.6.3.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Product
    • 11.6.4 South and Central America: Biologics Market Breakdown, by Application
      • 11.6.4.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Application
    • 11.6.5 South and Central America: Biologics Market Breakdown, by Source
      • 11.6.5.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Source
    • 11.6.6 South and Central America: Biologics Market Breakdown, by Manufacturing
      • 11.6.6.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
    • 11.6.7 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.6.7.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.6.7.2 Brazil: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.2.1 Brazil: Biologics Market Breakdown, by Product
        • 11.6.7.2.2 Brazil: Biologics Market Breakdown, by Application
        • 11.6.7.2.3 Brazil: Biologics Market Breakdown, by Source
        • 11.6.7.2.4 Brazil: Biologics Market Breakdown, by Manufacturing
      • 11.6.7.3 Argentina: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.3.1 Argentina: Biologics Market Breakdown, by Product
        • 11.6.7.3.2 Argentina: Biologics Market Breakdown, by Application
        • 11.6.7.3.3 Argentina: Biologics Market Breakdown, by Source
        • 11.6.7.3.4 Argentina: Biologics Market Breakdown, by Manufacturing
      • 11.6.7.4 Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.4.1 Rest of South and Central America: Biologics Market Breakdown, by Product
        • 11.6.7.4.2 Rest of South and Central America: Biologics Market Breakdown, by Application
        • 11.6.7.4.3 Rest of South and Central America: Biologics Market Breakdown, by Source
        • 11.6.7.4.4 Rest of South and Central America: Biologics Market Breakdown, by Manufacturing

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Biologics Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 AbbVie Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Pfizer Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Samsung Biologics Co Ltd
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 ADMA Biologics, Inc.
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 WuXi Biologics Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Catalent Inc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 AGC Biologics AS
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 AstraZeneca Plc
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Amgen Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Nitto Avecia
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Quality Assistance s.a.
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners

List Of Tables

  • Table 1. Biologics Market Segmentation
  • Table 2. Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Biologics Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 4. Biologics Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 5. Biologics Market - Revenue and Forecast to 2031 (US$ Million) - by Source
  • Table 6. Biologics Market - Revenue and Forecast to 2031 (US$ Million) - by Manufacturing
  • Table 7. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 8. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 9. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 10. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 11. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 12. United States: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 13. United States: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 14. United States: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 15. United States: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 16. Canada: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 17. Canada: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 18. Canada: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 19. Canada: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 20. Mexico: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 21. Mexico: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 22. Mexico: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 23. Mexico: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 24. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 25. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 26. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 27. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 28. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 29. Germany: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 30. Germany: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 31. Germany: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 32. Germany: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 33. United Kingdom: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 34. United Kingdom: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 35. United Kingdom: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 36. United Kingdom: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 37. Italy: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 38. Italy: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 39. Italy: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 40. Italy: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 41. France: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 42. France: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 43. France: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 44. France: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 45. Spain: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 46. Spain: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 47. Spain: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 48. Spain: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 49. Rest of Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 50. Rest of Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 51. Rest of Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 52. Rest of Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 53. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 54. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 55. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 56. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 57. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 58. China: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 59. China: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 60. China: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 61. China: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 62. India: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 63. India: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 64. India: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 65. India: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 66. Japan: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 67. Japan: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 68. Japan: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 69. Japan: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 70. South Korea: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 71. South Korea: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 72. South Korea: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 73. South Korea: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 74. Australia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 75. Australia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 76. Australia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 77. Australia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 78. Rest of APAC: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 79. Rest of APAC: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 80. Rest of APAC: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 81. Rest of APAC: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 82. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 83. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 84. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 85. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 86. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 87. South Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 88. South Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 89. South Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 90. South Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 91. Saudi Arabia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 92. Saudi Arabia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 93. Saudi Arabia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 94. Saudi Arabia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 95. United Arab Emirates: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 96. United Arab Emirates: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 97. United Arab Emirates: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 98. United Arab Emirates: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 99. Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 100. Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 101. Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 102. Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 103. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 104. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 105. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 106. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 107. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 108. Brazil: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 109. Brazil: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 110. Brazil: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 111. Brazil: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 112. Argentina: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 113. Argentina: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 114. Argentina: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 115. Argentina: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 116. Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 117. Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 118. Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 119. Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 120. Recent Organic Growth Strategies in Biologics Market
  • Table 121. Recent Inorganic Growth Strategies in the Biologics Market

List Of Figures

  • Figure 1. Biologics Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Biologics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Biologics Market Share (%) - by Product (2023 and 2031)
  • Figure 6. Monoclonal Antibodies: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Vaccine: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Recombinant Hormones/Proteins: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Cell and Gene Therapy: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Others: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Biologics Market Share (%) - by Application (2023 and 2031)
  • Figure 12. Cancer: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Infectious Diseases: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Autoimmune Diseases: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Others: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Biologics Market Share (%) - by Source (2023 and 2031)
  • Figure 17. Mammalian: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Microbial: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Biologics Market Share (%) - by Manufacturing (2023 and 2031)
  • Figure 20. Outsourced: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. In-house: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Biologics Market Breakdown by Region, 2023 and 2031 (%)
  • Figure 23. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 24. North America: Biologics Market Breakdown, by Product (2023 and 2031)
  • Figure 25. North America: Biologics Market Breakdown, by Application (2023 and 2031)
  • Figure 26. North America: Biologics Market Breakdown, by Source (2023 and 2031)
  • Figure 27. North America: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
  • Figure 28. North America: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 29. United States: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. Canada: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Mexico: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Europe: Biologics Market Breakdown, by Product (2023 and 2031)
  • Figure 34. Europe: Biologics Market Breakdown, by Application (2023 and 2031)
  • Figure 35. Europe: Biologics Market Breakdown, by Source (2023 and 2031)
  • Figure 36. Europe: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
  • Figure 37. Europe: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 38. Germany: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. United Kingdom: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. Italy: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. France: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. Spain: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Rest of Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Asia Pacific: Biologics Market Breakdown, by Product (2023 and 2031)
  • Figure 46. Asia Pacific: Biologics Market Breakdown, by Application (2023 and 2031)
  • Figure 47. Asia Pacific: Biologics Market Breakdown, by Source (2023 and 2031)
  • Figure 48. Asia Pacific: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
  • Figure 49. Asia Pacific: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 50. China: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. India: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. Japan: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. South Korea: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. Australia: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Rest of APAC: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 56. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. Middle East and Africa: Biologics Market Breakdown, by Product (2023 and 2031)
  • Figure 58. Middle East and Africa: Biologics Market Breakdown, by Application (2023 and 2031)
  • Figure 59. Middle East and Africa: Biologics Market Breakdown, by Source (2023 and 2031)
  • Figure 60. Middle East and Africa: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
  • Figure 61. Middle East and Africa: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 62. South Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 63. Saudi Arabia: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 64. United Arab Emirates: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 65. Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 66. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 67. South and Central America: Biologics Market Breakdown, by Product (2023 and 2031)
  • Figure 68. South and Central America: Biologics Market Breakdown, by Application (2023 and 2031)
  • Figure 69. South and Central America: Biologics Market Breakdown, by Source (2023 and 2031)
  • Figure 70. South and Central America: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
  • Figure 71. South and Central America: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 72. Brazil: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 73. Argentina: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 74. Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 75. Growth Strategies in Biologics Market